A Single-Center Prospective Natural History Study of RYR1-Related Disorders

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Background: Congenital myopathies (CM) are genetic disorders that can cause decreased muscle tone and muscle weakness. Most CMs in the United States are related to the ryanodine receptor 1 (RYR1) gene. Researchers need more natural history data to learn about these CMs in children and adults.

Objective: To learn more about the signs, symptoms, and course of RYR1-related disorders.

Eligibility: People aged 7 years and older with an RYR1-related disorder.

Design: Ambulatory participants will come to the Clinical Center and non-ambulatory participants will visit via telehealth. Visits will be once a year for 3 or 5 years. Clinical Center visits will take 2 to 3 days. All participants will undergo tests including: Photos and videos. These will be taken to document the participant s condition. Blood and urine tests. Activity Tracker. Participants will wear a device to record their activity. Questionnaires. Participants will answer questions about their health, pain, fatigue, stress, quality of life, and other topics. Participants who visit the Clinical Center will also undergo: Tests of heart and lung function. Motor skills and strength tests. Participants will walk, climb stairs, kneel, crawl, stand up, and perform other movements to test their strength and abilities. They will squeeze and pinch a handheld device to test their grip. Imaging scans. Skin biopsy. Adult participants may opt to have a sample of skin taken (one time only). Eye exam

Eligibility
Participation Requirements
Sex: All
Minimum Age: 7
Maximum Age: 100
Healthy Volunteers: f
View:

• Stated willingness to comply with all study procedures, availability for the duration of the study, and submission of medical records to research team prior to screening.

• Male or female, aged \> 7 years of age.

• Genetically confirmed RYR1-related disorder, evidenced by pathogenic or likely pathogenic variants identified by CLIA testing (whole genome, exome, targeted, partial or full RYR1 sequencing) OR variant of uncertain significance with supporting clinical phenotype.

• Ability of subject to communicate their understanding of the purpose of the study, and willingness to provide assent and/or sign a written informed consent document.

• Resides in the United States

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Irene C Chrismer, R.N.
irene.chrismer@nih.gov
(240) 591-8884
Backup
Tokunbor A Lawal, C.R.N.P.
lawalt@mail.nih.gov
(301) 451-5951
Time Frame
Start Date: 2025-03-11
Estimated Completion Date: 2031-12-30
Participants
Target number of participants: 150
Treatments
Centralized
Visits are conducted at the NIH clinical center. All participants are ambulatory.
Decentralized
Visits are conducted via telehealth.
Related Therapeutic Areas
Sponsors
Leads: National Institutes of Health Clinical Center (CC)

This content was sourced from clinicaltrials.gov